|
ARIH2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.68542957368345E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.40869538256538E-11 |
| Normal-vs-Stage2 |
1.80935999999354E-05 |
| Normal-vs-Stage3 |
1.93844940099552E-13 |
| Normal-vs-Stage4 |
6.43840536440621E-11 |
| Stage1-vs-Stage2 |
1.977400E-01 |
| Stage1-vs-Stage3 |
3.841800E-02 |
| Stage1-vs-Stage4 |
1.299220E-01 |
| Stage2-vs-Stage3 |
9.002100E-03 |
| Stage2-vs-Stage4 |
1.981740E-02 |
| Stage3-vs-Stage4 |
9.491400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.02424751907893E-13 |
| Normal-vs-AfricanAmerican |
3.71479999999869E-05 |
| Normal-vs-Asian |
1.37200000249749E-08 |
| Caucasian-vs-AfricanAmerican |
5.992000E-01 |
| Caucasian-vs-Asian |
3.815400E-01 |
| AfricanAmerican-vs-Asian |
9.813600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.1826986318938E-11 |
| Normal-vs-Female |
1.88848936488739E-12 |
| Male-vs-Female |
9.648200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.62554472291777E-12 |
| Normal-vs-Age(41-60Yrs) |
5.14199793855141E-11 |
| Normal-vs-Age(61-80Yrs) |
8.21365198078183E-12 |
| Normal-vs-Age(81-100Yrs) |
2.102100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.877000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.785800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.554800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.817200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.901200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.279400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.77910000065395E-08 |
| Classical-VS-Follicular |
9.582400E-01 |
| Classical-VS-Other |
3.461200E-01 |
| Classical-VS-Normal |
9.65538760056006E-12 |
| Tall-VS-Follicular |
1.95400000002621E-06 |
| Tall-VS-Other |
9.456100E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.329400E-01 |
| Follicular-VS-Normal |
3.12680000003063E-07 |
| Other-VS-Normal |
7.200900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.28008714739281E-12 |
| Normal-vs-N1 |
1.80560000284657E-09 |
| N0-vs-N1 |
2.458200E-01 |
|
|
